SecurityNAUBF / National Australia Bank Ltd. (Victoria, Australia)
Institutional Owners0

Institutional Stock Ownership and Shareholders

National Australia Bank Ltd. (Victoria, Australia) (OTC:NAUBF) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
National Australia Bank Ltd. (Victoria, Australia) (OTC:NAUBF) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

NAB pay revamp makes it much harder to reward bad behaviour

7h theage.com.au
National Australia Bank has provided the first insight into what bank remuneration schemes might look like in the wake of reforms to bank executives’ accountability prompted by the wave of finance sector scandals.

NAB pay revamp makes it much harder to reward bad behaviour

7h smh.com.au
National Australia Bank has provided the first insight into what bank remuneration schemes might look like in the wake of reforms to bank executives’ accountability prompted by the wave of finance sector scandals.

Banks' spring racing season begins with horse-trading on rates

15h theage.com.au
The National Australia Bank clawed back some customer goodwill a few weeks ago when it decided to break with the banking pack and leave its standard variable interest rate on hold for existing customers after the other banks announced rate hikes.

Banks' spring racing season begins with horse-trading on rates

15h smh.com.au
The National Australia Bank clawed back some customer goodwill a few weeks ago when it decided to break with the banking pack and leave its standard variable interest rate on hold for existing customers after the other banks announced rate hikes.

Customer suffering, scandals to slash bonuses in NAB's new pay system

17h theage.com.au
National Australia Bank's top brass, including chief executive Andrew Thorburn, could lose their bonuses if scandals happen under their watch, according to the bank's revamped pay scheme.